Free Trial
NASDAQ:SABS

SAB Biotherapeutics Q2 2025 Earnings Report

SAB Biotherapeutics logo
$2.20 -0.03 (-1.35%)
Closing price 04:00 PM Eastern
Extended Trading
$2.20 0.00 (0.00%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.82
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

SAB Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

SAB Biotherapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:00AM ET

SAB Biotherapeutics Earnings Headlines

Green Light for These Stocks
Guess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... becoming the largest shareholder in a critical mineral company tied to national security. Former hedge fund manager Whitney Tilson believes this is just the start of a sweeping plan to unlock trillions in hidden federal assets... from oil-rich land to rare earths and energy reserves. He says this could mark the beginning of the largest wealth transfer in modern U.S. history, and has identified the surprising areas where you could benefit.
SAB Biotherapeutics Inc (SABS) - Investing.com
See More SAB Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email.

About SAB Biotherapeutics

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

View SAB Biotherapeutics Profile

More Earnings Resources from MarketBeat